Welcome to PDS Biotechnology Corporation
PDS Biotechnology is a biopharmaceutical company developing the next-generation of simpler, safer and more effective treatments and preventions for cancer and chronic infectious diseases.
Stimulating the immune system has been demonstrated to be one of the most promising approaches to treating cancer and several debilitating and chronic infectious diseases, such as hepatitis and HIV.
PDS Biotechnology has developed a simple and synthetic nanoparticle technology known as Versamune™. This novel and superior cancer and vaccine nanotechnology platform is very effective in stimulating the immune system and training the immune system to recognize and fight the particular disease. To do so, a unique protein from the particular cancer type or virus is formulated and injected with Versamune™. In pre-clinical studies, very effective and superior treatment of advanced aggressive cancers with low doses of the Versamune™-based products has been demonstrated. The preclinical studies also demonstrated that the Versamune™-based products are exceptionally safe and well tolerated.
PDS Biotechnology is initially applying Versamune™ to the treatment of HPV- related cancers such as cervical cancer, oral cancer and cervical intraepithelial neoplasia (pre-cervical cancer). The HPV cancer immunotherapy is currently being evaluated in human clinical trials at clinics within the US.
PDS Biotechnology has also demonstrated superior efficacy with a novel and rapid acting Versamune™-based preventive pandemic influenza vaccine.
PDS recently signed a licensing agreement with a global pharmaceutical company, Merck KGaA, granting it a license to utilize PDS Biotechnology’s Versamune™ nanotechnology in the development of two new cancer therapies.